Natalizumab treatment for multiple sclerosis: Middle East and North Africa regional recommendations for patient selection and monitoring

BACKGROUND: Natalizumab, a highly specific α4-integrin antagonist, , has recently been registered across the Middle East and North Africa region. It improves clinical and magnetic resonance imaging (MRI) outcomes and reduces the rate of relapse and disability progression in relapsing-remitting multi...

Descripción completa

Detalles Bibliográficos
Autores principales: Alroughani, Raed A, Aref, Hany M, Bohlega, Saeed A, Dahdaleh, Maurice P, Feki, Imed, Al Jumah, Mohammed A, Al-Kawi, Muhammad Z, Koussa, Salam F, Sahraian, Mohamad A, Alsharoqi, Isa A, Yamout, Bassem I
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2014
Materias:
Research Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3927624/
https://www.ncbi.nlm.nih.gov/pubmed/24521176
http://dx.doi.org/10.1186/1471-2377-14-27

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3927624/
https://www.ncbi.nlm.nih.gov/pubmed/24521176
http://dx.doi.org/10.1186/1471-2377-14-27

Ejemplares similares